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Abstract 
Autoimmune rheumatic diseases are characterised by an abnormal immune system response, 
complement activation, cytokines dysregulation and inflammation. In last years, despite many 
progresses in managing these patients, it has been shown that clinical remission is reached in less 
than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in 
a significant gap between guidelines and real-world practice. In this context, the need for 
biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor 
outcome has become of crucial interest. A biomarker generally refers to a measured characteristic 
which may be used as an indicator of some biological state or condition. Three different types of 
medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. 
therapeutic markers. A combination of biomarkers from these different groups could be used for an 
ideal more accurate diagnosis and treatment.  However, although a growing body of evidence is 
focused on improving biomarkers, a significant amount of this information is not integrated on 
standard clinical care.  
The overarching aim of this work was to clarify the meaning of specific biomarkers during 
autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and 
suggesting specific treatments. 
 
 
Key words 
Biomarker; rheumatoid arthritis; spondyloarthritides; systemic sclerosis; systemic lupus 
erythematosus;  antiphospholipid syndrome; Sjogren’s syndrome. 
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1. Introduction 
Autoimmune rheumatic diseases are characterised by an abnormal immune system response, 
complement activation, cytokines dysregulation and inflammation [1]. These heterogeneous 
disorders may affect various organs, and although their clinical presentations may be different, 
these diseases share significant genetic risk factors and common regulatory mechanisms [2]. 
Environmental and female-associated factors also play pathogenic roles in development of 
autoimmune diseases [1,2].  In last years, despite many progresses in managing these patients, it has 
been shown that clinical remission is reached in less than 50% of patients and a personalised and 
tailored therapeutic approach is still lacking  resulting in a significant gap between guidelines and 
real-world practice [3,4]. In this context, the need for biomarkers facilitating early diagnosis and 
profiling those individuals at the highest risk for a poor outcome has become of crucial interest 
[5,6]. A biomarker generally refers to a measured characteristic which may be used as an indicator 
of some biological state or condition [7]. Three different types of medical biomarkers has been 
suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers [8]. In the 
first group, subcellular changes may lead to alterations in proteins detectable as biomarkers and 
reflecting the ongoing cellular process and  manipulated signalling pathways [9]. In the second 
group, the disease development is associated with the changes in proteins that are detected by 
proteomics, defining the clinical disease markers, which indicate state of progression, severity and 
location of the disease [10]. In the third group, the treatment of a disease may point out  therapeutic 
biomarkers, associated with a specific changing pattern after the drug administration [11]. Taking 
together these observations, a combination of biomarkers from these different groups could be used 
for an ideal more accurate diagnosis and treatment.  However, although a growing body of evidence 
is focused on improving biomarkers [7-11], a significant amount of this information is not 
integrated on standard clinical care.  
The overarching aim of this work was to clarify the meaning of specific biomarkers during 
autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and 
suggesting specific treatments. 
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2. Methods 
 
2.1 Aims of the project 
The overarching aim of this workshop is to clarify the meaning of specific biomarkers during 
autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and 
suggesting specific treatments. The general methodology based on a Delphi Technique-based aimed 
at producing, starting from the results of a systematic review of available literature, a set of 
statements summarising the consensus among the Experts, as previously reported [12]. This 
systematic review has been designed to be included in an International project named “Clinical and 
biological biomarkers in conventional and/or biological therapies. From pathology to treatment: 
what evidence in rheumatic and autoimmune diseases? 2th International workshop” aimed to 
update some features in management of patients affected by autoimmune disease. As a part of an 
International project, a Scientific Committee composed by a group of experts and bibliographic 
fellows identified some relevant clinical questions on biomarkers in autoimmune diseases, needing 
further and updated clarifications according to available scientific evidence and joined Experts’ 
opinion. These invitations were a consequence of the individuals’ contributions to the specific fields 
included in the topics of the meeting as well as deliberations among members of the steering 
committee. Six autoimmune diseases were selected and evaluated: rheumatoid arthritis (RA), 
spondyloarthritides (SpA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), 
antiphospholipid syndrome (APS), primary Sjogren’s syndrome (pSS). These topics were 
developed and updated throughout an extensive bibliographic review by the Steering Board, after 
joining common limits and methods of search. For each selected topic, preliminary statements 
based on available scientific results have been presented in accordance with their level of evidence, 
discussed, eventually reformulated, and voted through a Delphi-method during a Consensus 
involving a panel of International Experts. Statements supported by ≥ 66% of votes were accepted 
as final statements, while the others were rejected outright. This project has been concluded in Italy 
on October 6-7, 2017.  
2.2 Search Design 
For each of these 6 topics, a systematic literature search was performed in indexed international 
Journals (Medline via Pubmed, Scopus, Cochrane database). The Scientific Committee decided to 
analyse the literature from July 1, 2007 – July 1, 2017. The choices of temporal limits, online 
databases and methodology were originally discussed and shared by participants in order to gain 
homogeneous results.  
2.3 Search Strategy 
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The search strategy combined indexed and free-text terms, interventions and outcomes of interest in 
Medline via Pubmed, Scopus, Cochrane database, as requested for each single topic. PICO strategy 
was also joined as shared rephrasing strategy across working groups, along with pre-defined 
“Population”, “Intervention”, “Comparison”, “Outcomes”, as requested by single topic research 
question. The main search was thus formulated using a string of relevant terms of research. In 
addition, the main keywords were used in different combinations in order to improve the sensitivity 
of the search strategy. The bibliography of relevant articles was also hand-searched for 
identification of other potentially suitable studies. 
2.4 Eligibility Criteria 
Included studies were full-text manuscripts in English language conducted in adult patients with 
autoimmune diseases. To be included in the final analysis, studies had to meet the following joined 
inclusion criteria: 1) study design: systematic review and meta-analysis, randomised controlled trial 
(RCT), quasi-RCT (trials in which allocation to treatment was made by alternation, use of alternate 
medical records, date of birth or other expected methods), observational cohort studies or case 
series; 2) data concerning population, intervention, comparison and outcomes were requested for 
each single selected topic. Narrative reviews, editorials, scientific conference abstracts, case reports 
and pre-clinical studies have been excluded from the purpose of this work. Papers retrieved by 
literature search but reporting insufficient data according to selected PICO strategy were excluded 
from the review. The hierarchy of study types was indicated by levels of evidence suggested by 
Oxford University (http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-
march-2009/). 
2.5 Study Identification and data extraction 
In each group working on a single topic, full-text articles were screened and selected analysing titles 
and abstracts by bibliographic fellows, then independently verified by corresponding senior 
reviewers. After the screening phase, the bibliographic fellows also independently evaluated the 
selected abstracts and the full-text of these studies to determine eligibility according to the 
eligibility criteria. Any uncertainties and/or disagreements were resolved by discussion until 
reaching a final consensus. Data extraction was also performed by bibliographic fellows and 
independently verified by corresponding senior reviewers. After that, the results of the analysis of 
literature were summarised, presented, and further inputs were obtained from expanded working 
groups with other authors. Conflicting results were analysed by discussion taking into account 
quality of assessed studies until reaching an agreement into the single working group. The 
statements were thus formulated according to results and quality of evaluated works. Further 
disagreements were resolved by discussion until reaching a final consensus. In the subsequent 
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plenary session, the statements were subjected to be voted as ‘yes’ (agreement) or ‘no’ 
(disagreement) from the entire panel of Experts. Statements supported by ≥ 66% of positive votes 
were accepted while the others were rejected outright. At this final stage, only suggestions for 
improvements of clarity of wording or addressing redundancies were considered, while any change 
to the meaning was not accepted. 
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3. RA Working Group 
To date, recognition and better definition of disease-specific biomarkers, easily and routinely 
detectable in patients serum samples, could be relevant for diagnostic and prognostic purposes in 
the view of a more patients’ tailored approach, regardless of the underlying condition. Anti-
citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are well recognized clinically 
relevant biomarkers in rheumatoid arthritis (RA) patients [13]. Their pathogenic role has been well 
characterized, being detectable in the serum in pre-clinical phase many years before clinical 
presentation of the disease.  Moreover, both biomarkers have been included in the new 2010 RA 
classification criteria into a score-based algorithm where both qualitative (negative versus positive) 
and quantitative (low level versus high level) evaluations have been inserted, with high level 
(predefined as ≥3 times the ULN for the laboratory test and assay) having greater weight in 
substantially contributing to RA diagnosis [14].  In the 2016 update of EULAR recommendations 
for RA management, either presence and levels of RF and/or ACPA have been listed among several 
other prognostic factors to be considered during therapeutic management, too. Moving from this 
starting point, it could be clarified whether a better definition of such biomarkers (high versus low 
serum levels) might help clinicians in  term of discriminative ability in diagnostic accuracy (as 
diagnostic and differential diagnostic tool) and prognostic stratification (disease course, 
radiographic damage, response to therapy). In other words, throughout an extended systematic 
review on the topic in line with joined pre-specified limits and settings, the clinical meaning of 
“level criterion” of “serology” item has been investigated in light of diagnostic and prognostic 
purposes (see corresponding PICOs rephrasing in Table1/in the attached files). Any case, when 
interpreting lab results of RA serum biomarkers, several concerns might be taken into account 
justifying contrasting results across studies: lack of harmonization and standardization of RF and 
ACPA tests (different methods, cut-off levels, reference materials);  assessment of different RF 
isotypes (IgG, IgA, IgM) and ACPA specificities; disease and demographical characteristics of 
enrolled RA patients (ethnic and genetic background of target populations, disease duration, 
environmental exposition); lastly, when considering the impact of biomarkers on prognosis, 
previous and current treatment itself might be a confounding factor, too. Moreover, as a further 
source of heterogeneity and variability, different definitions of high and low levels of either RF 
and/or ACPA have been proposed across studies, mostly in accordance to EULAR/ACR 2010 
classification criteria (3 times higher the cut off values) [14].  
 
3.1 Diagnostic purposes, the role of anti-CCP 
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In a population-based setting, higher level of anti-cyclic citrullinated peptide (anti-CCP), 
defined as ≥3-fold the ULN, might be more clinically useful for RA diagnosis. LoE 2b 
Two population-based studies assessed in large unselected cohorts the discriminatory capacity of 
anti-CCP in diagnosing RA for either prevalent (cross-sectional analysis) and incident (prospective 
analysis) cases [15,16]. These studies offered the unique advantage of testing such biomarker in 
numerous healthy (independently of any previous/current sings and/or symptoms of arthritis or any 
previous lab measurement) rather than selected subjects, like blood donors or high-risk populations 
(symptom-free first degree relatives of RA patients, patients with arthralgia,  patients suffering from 
other autoimmune diseases). In both studies high anti-CCP levels have been defined in accordance 
to ACR/EULAR 2010 classification criteria. In the study by Hensvold, high versus low anti-CCP2 
titers were associated with increased specificity for prevalent RA with only minor decrease in 
sensitivity (98% and 66% and 99% and 62% with positive anti-CCP2 and high anti-CCP2 cut-off, 
respectively). In the study by Demourelle et al [15], when prevalent cases were considered 
(established RA patients), the higher the adopted anti-CCP cut-off levels, the better the specificity 
(93.1% using standard cut-off level, 97.2% with ≥ 3 X standard cut-off level for anti-CCP3 assay). 
Despite this, it remains debatable whether a single assay with a common threshold could be 
considered optimal for all clinical settings.  
RF positivity together with very high levels of anti-CCP might be useful to discriminate RA 
patients from other rheumatic diseases.  LoE 3 
We identified 6 research articles that compared anti-CCP test in term of discriminative diagnostic 
performance in patients suffering from RA or other RA-mimicking rheumatic or non-rheumatic 
diseases [17-22].   All of them have case-control design involving as control population patients 
with non-RA inflammatory and non-inflammatory rheumatic diseases (osteoarthritis, systemic lupus 
erythematosus, Sjogren’s syndrome, spondyloarthritis, systemic sclerosis, crystal-induced arthritis, 
infectious arthritis, systemic sclerosis, fibromyalgia, and/or other related conditions) [17-22]. The 
underlying hypothesis is that elevated anti-CCP levels, as more specific RA markers respect to RF, 
can help in better supporting the differential diagnosis of RA and the above indications. In the 
largest study by Pietrapertosa, specificity and sensitivity of anti-CCP2 antibodies measured by 
ELISA were tested in 787 patients with RA, 1024 patients with other autoimmune/inflammatory 
rheumatic disease and 401 subjects without autoimmune rheumatic diseases (osteoarthritis and 
fibromyalgia) [22].Using ROC curve analysis, the cut-off value of 2.8 U/mL for anti-CCP2 had the 
highest diagnostic accuracy for distinguishing between RA patients and both control cohorts, but a 
value of anti-CCP2 15 U/mL (3 fold the manufacturer cut-off) was associated with a significant 
increase in the likelihood of RA disease. In addition, in a Chinese population, the combination of 
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high titer anti-CCP antibodies (≥100 RU/ml) with a concomitant positive RF test exhibited the 
greatest diagnostic specificity, especially in the early stage of the disease, respect to single positive 
RF and/or anti-CCP or double positive or RF+ and low positive anti-CCP [20]. Contrasting results 
come from a French and Korean studies, where anti-CCP level (high versus levels) did not offer 
further information in discriminating RA from other non RA diseases: anti-CCP positivity resulted 
significantly more prevalent in RA patients, whereas high titers anti-CCP, when positive, did not 
substantially differ across rheumatic RA and non RA conditions [18,21]. 
 
3.2 Prognostic purposes, RF and anti-CCP 
High levels of anti-CCP and/or RF seem to correlate with higher disease activity and worse 
radiographic progression over time. High titre anti-CCP and RF are correlated with better 
response to rituximab, while only very high anti-CCP titers seem to be associated with better 
response to abatacept. LoE 2b. 
3.2.1 Radiographic progression 
Globally, high levels of either RF and/or anti-CCP were significantly associated with worst 
deterioration over time in RA patients [23-31]. In the study by Syversen, et al. among 125 
established RA patients, anti-CCP considered either as categorical and quantitative parameter was 
significantly associated with radiographic progression according to the van der Heijde modified 
Sharp score of the hands at 10-year assessment [23]. Anti-CCP (OR 4.0; 95% CI 1.6 to 10.0) was 
the strongest independent predictor of radiographic progression, in a level-dependent fashion:   
respect to  anti-CCP-negative patients, low to moderate (25–200 U/ml) and high levels (>200 U/ml) 
anti-CCP subjects were more likely to develop radiographic progression over time (corresponding 
Odds Ratios/OR being 2.6, 95% CI 0.9 to 7.2 and 9.9, 95% CI 2.7 to 36.7, respectively). Higher 
cut-off RF levels did not change the model, without improving or weakening the prognostic effect 
of anti-CCP. Conversely, in a cohort of Japanese early RA patients (disease duration <2 years), 
median total Sharp score at 2 years did not significantly differ among baseline low-titre (median 
score [IQR] 23.0 [8.0, 47.3]) versus high-titre (21.5 [7.5, 52.0]) anti-CCP groups; nevertheless both 
subgroups substantially differed respect to  anti-CCP negative patients ( 2-year median Sharp score 
[IQR]  6.0 [2.0, 12.0], p=0.00001 versus low- anti-CCP p=0.00001 versus high-anti-CCP ) [27]. 
Different target populations (established versus early disease in divergent ethnic background), 
outcome time-points (10-year versus 2-year), anti-CCP cut-off pre-defined levels, might account 
partly for divergent results between these 2 studies [30]. A level-dependent effect on structural 
outcome was confirmed for RF-titers too, in line with Van der Linden study [25].  Regardless of the 
given definition, high RF levels (defined as >3 cutoff value, as in the 2010 ACR/EULAR 
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classification criteria or RF>50 units/ml/RF50, in line with definition given by previous studies) 
were significantly associated with a higher risk of radiographic progression over 7 years in 686 RA 
patients; nevertheless the association between high RF level and RA severity was not as strong as 
that between anti-CCP positivity and RA severity, with significantly greater progression rate for 
ACPA+ versus both high RF levels definitions. Similarly, pooled data from five clinical trials 
demonstrated a significant RF level-dependent effect (RF−, RF low+, RF high+)   on radiographic 
damage (proportion of progressors  and of rapid progressors) in the study by Aletaha,  after 
adjustment for relevant and confounding parameters like disease duration, baseline damage, 
baseline CRP and baseline ESR [28]. In addition, even in case of DMARDs-induced disease 
control, high level ACPA (> 48 U/mL, as defined through ROC curve) resulted the strongest 
independent predictor of clinically relevant radiographic progression in a real world Japanese 
prospective study. Possibly, an additive effect between ACPA and RF could be taken into 
consideration when considering RA structural damage: only in ACPA positive RA patients, TC-
detected erosion burden at hands (number and size of erosions)  was cross-sectional  associated with 
RF-levels; thus, RF might act as a structural damage enhancer only in ACPA-positive patients in a 
dose-dependent manner [26].  
3.2.2 Disease activity 
Higher anti-CCP and RF concentrations resulted associated with greater disease activity over time 
along with lower chance to achieve sustained remission in men with established RA mainly under 
csDMARDs background [32,33]. Similarly, baseline low RF and anti-CCP levels (arbitrarily 
chosen by the authors) were independently predictive of clinical remission and low disease activity 
achievement at 12 months in 90 Romanian RA patients starting their first TNFi. High anti-CCP 
titers significantly correlated with higher RF levels, DAS28 score and more severe morning 
stiffness duration in a Chinese population by Li et al [20]. 
3.2.3 Response to therapy 
The systematic review by Salgado included  two studies considering the impact of RF levels (high 
versus low) on TNFi response: only the one by Klaasen enter our review due to publication date 
[34,35].  Among 101 RA patients eligible to infliximab, presence and high (>100 UI/mL) levels of 
RF-IgM significantly and positively correlate with primary response to therapy at 16 weeks, while 
high RF-IgG and RF-IgA did not. On the contrary, in the study by Salgado no significant 
differences across 50th, 25th and 75th percentiles of baseline IgM RF titers were observed between 
responders and non-responders ( EULAR response criteria at 24 weeks) in a combined cohort of 3 
Spanish centres experience [36]. Such contrasting results for RF levels and TNFi response are in 
line with previous published reports on the topic [37]. High levels of aCCP (>400 UI/mL) resulted 
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significantly associated with greater probability of achieving ACR20 response after 16 weeks of 
adalimumab medication in a cohort of 70 RA patients [38]. Similarly, among 108 RA patients those 
with baseline anti-CCP titers>300 UI/mL  were more likely (more than 3 times) to gain major 
EULAR response 6 months after the first rituximab cycle after failure of at least one TNFi in the 
retrospective analysis by Narvaez et al. [39]. Finally, from the post-hoc analysis of the AMPLE trial 
as a head-to-head comparison between adalimumab and abatacept on a MTX background in MTX-
IR patients, baseline anti-CCP2 positivity was associated with a better clinical response to both 
ABA and ADA. Nevertheless, only in ABA group, patients with the highest (fourth quartile, 
corresponding to very high levels, 1060–4894 AU/mL) vs lower CCP2 concentrations (Q1) had 
better clinical response with ABA; this association was not observed in ADA group. Despite not 
designed and powered for such comparison, there was no inter-group difference in term of clinical 
response between the highest quartile group patients belonging to ADA or ABA group [40].  
In RA patients, auto-antibodies like RF and ACPA represent the hallmark of the break of immune 
tolerance, accompanying and justifying both the onset and the burden of  the disease itself. Very 
recently, the “level criterion” of such biomarkers entered into both classification and prognostic 
stratification criteria. In line with retrieved scientific evidences, joined by an international panel of 
expert rheumatologists, a better definition of either RF and ACPA in term of high versus low levels 
might add relevant information for diagnostic and prognostic purposes, thus supporting clinicians 
for a more specific disease recognition and prognostic stratification. To date, efforts should be 
pointed out to harmonize and standardize biomarkers detection in order to allow comparison and 
generalization of results either at a research level, and in  the everyday clinical setting. 
 
3.3 Anti-CarP in predicting more severe RA course 
Anti-CarP antibodies may serve as predictors of more severe radiographic progression in RA 
and potentially associated with more severe disease course. LoE 2b 
Antibodies against carbamylated proteins (anti-CarP antibodies), recognising proteins post-
translationally modified by a process of carbamylation, have been recently detected in rheumatoid 
arthritis (RA) [41-43]. In this systematic review of literature, we investigated the prognostic role of 
anti-CarP antibodies in predicting more severe RA course. After screening titles and abstracts, 5 
observational studies were retrieved and included in the review [44-48]. 
Shy et al assessed anti-CarP in sera from 571 RA patients by Leiden EAC cohort and 305 healthy 
controls [44]. Authors reported 45% of RA patients were positive for IgG anti-CarP antibodies and 
43% positive for IgA anti-CarP antibodies. Furthermore, anti-CarP antibodies were associated with 
a more severe radiographic damage over 7 years, analysing all enrolled patients. Of note, anti-CarP 
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IgG antibodies were associated with a more severe radiological progression also in ACPA-negative 
RA [44]. These findings have been replicated in subsequent studies, assessing anti-CarP antibodies 
to be an independent predictor of radiographic progression [45,46]. Ajeganova et al assessed 576 
Swedish and 628 Dutch patients and observed anti-CarP antibodies were associated with more 
severe radiographic progression over 8 years in all included and ACPA-negative RA patients [45]. 
Similarly, Brink et al reported a more severe radiographic damage in 42.2% of RA patients positive 
for such antibodies over 2 years [46]. Anti-CarP antibodies have been also correlated with 
subclinical atherosclerosis and mortality in RA patients [47,48]. In the study by Spinelli et al, the 
association between anti-CarP antibodies and measures of endothelial dysfunction, used as markers 
of subclinical atherosclerosis, was described in 50 RA patients [47]. Finally, in a Spanish cohort of 
331 RA patients, Vidal-Bralo et al reported a correlation between anti-CarP antibodies and 
mortality in RA over a period of 9 years follow-up [48].  
Despite providing a synthesis of available literature, our systematic review is impaired by different 
limitations, mainly due to lack of standardization of tests analysing anti-CarP antibodies and 
different RA characteristics across evaluated studies (i.e. different disease durations and applied 
classification criteria).  
 
3.4 The possible role of MBDA in RA management 
In RA, the possible role of MBDA in predicting disease course and response to treatments is 
still controversial. LoE 5 
Multi-biomarker disease activity (MBDA) test has been developed evaluating serum levels of 12 
proteins associated with RA disease activity [49,50]. In this systematic review of literature, we 
investigated the role of MBDA in RA, assessing its predictive role of radiographic progression and 
response to treatments. After screening titles and abstracts, 6 observational studies were retrieved 
and included in the review [51-56].  
Conflicting results are published assessing the predictive value of MDBA for radiographic 
progression. In the study by Bakker et al, MBDA was not identified as predictor of radiographic 
progression over 2 years analysing 120 sera from CAMERA study, despite the association with 
disease activity [51]. Similarly, analysing sera and outcomes of 171 RA patients enrolled in the 
DRESS study, MBDA score was not predictive of radiographic progression, neither of successful 
tapering or subsequent flare, in patients who tapered TNFi [52]. In contrast, Hambardzumyan et al. 
reported MBDA score was an independent predictor of radiographic progression, analysing 235 RA 
patients from SWEFOT trial, after 1 year of follow-up [53]. Furthermore, associations between 
MBDA score and imaging findings of radiographic damage, were investigated in 52 RA patients 
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enrolled in HURRAH trial, by using magnetic resonance imaging (MRI), ultrasonography (US), 
computed tomography and radiography. Despite the fact that the MBDA score poorly correlated 
with MRI/US indexes of inflammation, elevated values were determined in patients characterised 
by more severe radiographic damage [54]. 
Analysing MBDA and response to treatment, Hambardzumyan et al. described the MBDA to be 
predictive for optimal add-on treatment in non-responder RA patients [55]. Authors assessed data 
from 157 patients enrolled in SWEFOT trial, after 3 months of methotrexate (MTX) therapy. A 
significant percentage of patients characterised by a low MBDA score experienced a good clinical 
response to subsequent triple therapy (MTX+sulfasalazine+hydroxychloroquine), whereas in 
patients displaying a high MBDA score, a significant percentage experienced a good clinical 
response to subsequent combination therapy with TNFi (MTX+infliximab) [55]. Finally, in the 
analysis of RETRO study MBDA scores were investigated to be predictive of disease relapse. 
RETRO was a phase-3, multicentre, randomised, open, prospective, controlled, parallel-group study 
in patients were allocated to continue conventional and/or biological DMARD regimen at full dose 
for 12 months, to reduce the dose of all conventional and/or biological DMARDs by 50% or to 
reduce the dose of all conventional and/or biological DMARDs by 50% for the first 6 months 
before to entirely stop all DMARDs. The results showed that higher values of MBDA scores in 
patients experiencing disease relapse after tapering and/or stopping conventional and/or biological 
DMARDs treatment, allowing a prediction of relapse in more than 80% of the patients [56]. 
Future specific designed and adequately powered studies with a longer follow up are needed to fully 
clarify the role of MBDA in management of RA patients, in predicting radiographic progression as 
well as response to therapeutic strategies.  
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4. Spondyloarthritides Working Group 
The spondyloarthritis (SpA) complex includes a group of inflammatory rheumatic diseases with 
peculiar clinical and radiological features including sacroiliitis, enthesitis, and dactylitis [57]. 
Among SpA, psoriatic arthritis (PsA) is characterized for a broad and heterogeneous spectrum of 
clinical features and courses [58,59]. In some cases, PsA can occur with peripheral enthesitis, 
particularly Achilles tendinitis, and/or dactylitis [60,61]. In the last decades, an increasing attention 
has been paid to the erosive and deforming course of PsA (40%–60% of patients) [62]. The 
identification of clinical and biological predictors of response to different biological disease-
modifying anti-rheumatic drugs (bDMARDs) might help clinicians to make evidence-based 
decisions that maximise the benefits from treatment by targeting subsets of patients.  In addition, 
this approach could also improve the cost/benefit and benefit/risk ratios in patients selected to start 
bDMARDs treatment [63].  
 
Although enthesitis may be considered a clinical markers of PsA, there is no evidence showing 
that its presence at baseline predicts the response to different bDMARDs (TNFis, IL17is, 
IL12/IL23is). LoE 5 
Enthesitis is the inflammation of the insertion of tendons and ligaments into the bone and represents 
a hallmark of PsA and other SpA [64].  It can be considered among the first signs of PsA, occurring 
independently of arthritis [60]. The role of enthesitis as a predictor of treatment response in 
ankylosing spondylitis (AS) has been well defined in 2011 by Vastesaeger et al [65]. Thereafter, in 
2013, in a retrospective study, Spadaro and coworkers showed that in AS patients treated with 
adalimumab, etanercept or infliximab, the probability of obtaining partial remission was 
significantly lower when enthesitis was present at baseline [66]. In PsA patients, there are no 
studies evaluating the role of enthesitis as an independent clinical biomarker predicting the response 
among different bDMARDs (TNFis, IL17is, IL12/IL23is). 
 
Although data available on biomarkers for predicting therapeutic response in SpA are scarce, 
CRP in clinical practice may be useful in predicting TNFis response. LoE 2b 
Only few articles addressed the potential role of soluble biomarkers in prediction of treatment 
response to TNFis in SpA patients. The majority of these studies were characterised by a weak 
methodology, mainly due to low power or lack of power calculation and an uncontrolled design. 
Amongst the potential biomarkers, baseline serum levels of matrix metalloproteinase-3 (MMP-3) 
[67,68], serum type I collagen C-telopeptide (sCTX) [69], complement fraction C3 [70], serum 
amyloid A (SAA) [71], anti-drug antibodies (ADAbs) [72], and IL-6 [73] have been reported to 
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predict treatment response in individual studies. Moreover, two well-designed sub-studies of RCTs 
evaluated the predictivity of a large pool of soluble biomarkers in AS and PsA [74,75]. In 
particular, baseline levels of insulin, apolipoprotein C3, leptin, haptoglobin, IL-6, osteocalcin, 
procollagen type 1 amino-terminal propeptide (P1NP) and deoxypyridinoline were associated with 
ASAS20 response at week 14 in AS patients while baseline levels of adiponectin, prostatic acid 
phosphatase (PAP) and vascular endothelial growth factor (VEGF) predicted at least two out of the 
three clinical endpoints (ACR20, DAS28, PASI75) after 14 weeks in PsA patients. The results of 
the systematic review showed that only higher baseline C-reactive protein CRP values were 
consistently reported to predict response to treatment with TNFis in SpA patients, although this 
evidence relies mainly on observational studies [71,74,76] and only one RCT [73]. 
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5. SSc Working Group 
SSc has the highest fatality rate among connective tissue diseases and is characterized by cellular 
and humoral immunological abnormalities, fibroproliferative vasculopathy, and fibrosis of the skin 
and various internal organs. Pulmonary involvement, including both interstitial lung disease (ILD) 
and pulmonary arterial hypertension (PAH) is currently the primary cause of morbidity and 
mortality in SSc [77]. The course of ILD is highly variable, and patients may develop severe and 
rapidly progressive interstitial lung involvement during the early phase of the disease, while others 
may have a limited and non-progressive course [78-81]. The clinical course of untreated PAH is in 
most cases rapidly progressive leading to respiratory failure or death within 2–3 years after it 
becomes clinically detectable [82]. In this context, the identification of biomarkers for assessing 
certain phenotypes associated with an increased risk of developing severe and rapidly progressive 
ILD and/or PAH is extremely important [83]. At present, despite intense investigation, only a few 
biomarkers for SSc have been fully validated and widely accepted. On this background, five 
statements were formulated and voted.  
 
Anti-topoisomerase 1 antibody is a biomarker for faster progression of SSc-ILD. LoE 2b  
Anti-topoisomerase 1 antibody is directed against DNA topoisomerase I and is strongly associated 
with the diffuse form of SSc (dcSSc) and with the development and/or faster progression of ILD. 
The Genetics versus Environment in Scleroderma Outcome Study (GENISOS), based on a 
prospective, observational cohort of 266 patients with early systemic sclerosis, confirmed that the 
presence of anti-topoisomerase 1 antibody was the only variable associated with differential forced 
vital capacity (FVC) levels, predicting the rate of decline in FVC within the first 3 years of follow-
up [80]. Subsequently, a study cohort consisting of 398 consecutive SSc patients with  follow-up for 
up to 15 years confirmed that anti–topoisomerase 1 antibody remained remains a significant 
predictor of the development of clinically significant pulmonary fibrosis (PF) together with other 
variables such as dcSSc, lower FVC, and lower diffusing lung capacity for carbon monoxide 
(DLCO). In this study, SSc-ILD was confirmed by high-resolution computed tomography, and 
clinically significant SSc-ILD was defined as FVC or DLCO ≤55% predicted or a documented 
decline in FVC or DLCO of ≥15% [84]. However, there is no consensus for the definition of ILD 
progression.  
 
KL-6, SP-D, CCL18 may be considered as biomarkers for short-term progression of SSc-ILD. 
LoE 3b  
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Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D) and CC-chemokine ligand 18 
(CCL18) are proteins produced and secreted by alveolar type II epithelial cells and alveolar 
macrophages, and were found to be increased in the serum of SSc patients compared to healthy 
subjects, and even further increased in SSc-ILD patients. Furthermore, these proteins appear to 
predict the development of SSc-ILD and subsequent FVC decline, in the short-term as well [85-94]. 
It is important to highlight that the definition of “short-term” ILD progression is herein defined as 
progression within 12 months, which reflects the duration of clinical trials in SSc-ILD.  
CCL18 serum levels predicted SSc-ILD progression in one study [86]. These results were, 
subsequently, confirmed in a second independent cohort of SSc patients, with a different, lower cut- 
off value of CCL18 [87]. However, these differences in cut-off levels highlight the need of 
standardization of CCL18 assays, before its use as a biomarker in clinical practice [88]. 
Furthermore, increased serum KL-6 was identified as an independent predictor of subsequent FVC 
decline [89-91] and associated with ILD activity [92]. Finally, increased serum SP-D, was a 
significant predictor of FVC decline [92,94]. 
 
The DETECT algorithm is useful to identify SSc patients at higher risk for PAH who should 
undergo RHC. LoE 2a  
In a large, multicentre, cross-sectional, study, the DETECT algorithm, a composite biomarker 
which uses clinical variables, pulmonary functional tests, immunological, biological, 
electrocardiographic and echocardiographic parameters, proved to be a useful tool, to identify 
patients who are more likely to have PAH, especially those who are asymptomatic. A positive score 
justifies performing right heart catheterization for confirmation of PAH [95]. Subsequent work by 
different research groups in different cohorts of patients with SSc confirmed the validity of this 
composite biomarker as an excellent screening method due to its high sensitivity and predictive 
negative value, minimizing missed diagnosis of PAH [96,97], also comparing it with European 
Society of Cardiology/European Respiratory Society (ESC/ERS 2009) guidelines [98]. Nonetheless, 
it should be kept in mind that the DETECT score was developed for SSc patients with low DLCO 
and disease duration > 3 years and is therefore validated in this particular patient group.  
 
High levels of plasma CXCL4 may predict development of PAH in SSc patients. LoE 2b 
CXCL4 is a pro-inflammatory chemokine that regulates immune cells, such as T cells, monocytes, 
dendritic cells, as well as non-immune cells like endothelial cells, and may have an important role 
in inflammation and wound repair [99,100]. Recently, a proteome-wide analysis has demonstrated 
that CXCL4 is the predominant protein produced by SSc-derived plasmacytoid dendritic cells and it 
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was identified as a potential biomarker associated with multiple organ involvement in SSc. Elevated 
plasma levels of CXCL4 strongly correlated with the extent of skin and lung fibrosis, as well as 
with early PAH development [101]. Despite the high LoE and GoR of the study, to date, no 
additional study has confirmed these data. 
 
High levels of serum Anti-AT1R and Anti-ETAR antibodies may predict development of PAH 
in SSc. LoE 2b  
Autoantibodies against the angiotensin II type 1 receptor (AT1R) and the endothelin-1 type A 
receptor (ATAR) have been shown to be elevated in the sera of most SSc patients, and associated 
with vascular and fibrotic SSc complications [102,103]. In particular, both anti-AT1R and anti-
ETAR antibodies are predictive and prognostic markers of SSc-PAH [104].
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6. SLE Working Group 
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where treatment is usually 
long-term or even life-long. One of the most controversial aspects of the management of SLE lies in 
the need to define a treat-to-target strategy, developed under the influence of evidence, to tailor to 
individual patients [105]. Even if to date a generally accepted definition of remission is lacking, in 
recent years several studies have shown that remission is a pursued and reachable target in SLE that 
positively impact disease outcomes halting accrual of organ damage [106-108]. The disease 
management during remission is an outstanding unmet need in SLE and EULAR task force 
suggested that is not recommended to escalate the treatment in clinically asymptomatic patients 
solely on stable or persistent serological activity [105].  
Despite significant advances in pathogenic knowledges and therapy, SLE is still burdened by 
significant morbidity and mortality. Epidemiological studies show that the goal of prolonged 
remission or low disease activity is achievable only in a part of SLE patients [106]. The majority of 
patients experience frequent disease flares, significant undesirable effects of treatments and 
irreversible organ damage accrual [109]. The development of new drugs and the use of available 
therapies in the framework of a treat-to-target approach might be essential to improve the long-term 
prognosis of the disease [105]. Belimumab, a monoclonal antibody directed against the B-cell 
activating factor (BAFF) [110], is the first drug approved for the treatment of SLE. Randomized 
clinical trials and real life studies demonstrated the efficacy of Belimumab in reducing  disease 
activity and flares, sparing glucocorticoids, improving fatigue and health related quality of life and 
in preventing damage accrual [111,112]. However, literature data and daily life clinical practice 
clearly demonstrated that only a part of SLE patients adequately respond to Beimumab [113]. The 
identification of drug response biomarkers could be crucial to optimize the use of Belimumab in 
SLE.   
 
There is no evidence that a negative serology predicts a successful withdrawal of therapy in 
SLE patients (with or without nephritis) in clinical remission. LoE 5 
Although the topic concerning treatment withdrawal is a priority aspect in the management of 
patients with SLE, the currently available data on this topic are still very fragmented. Reviewing the 
existing literature, it has not been possible to find studies that answer directly to our research 
questions reformulated according to the PICO methodology, nor to identify trials designed for 
evaluating treatment withdrawal in inactive SLE patients with negative serology. No data are 
available to suggest the optimal duration of treatment in responsive patients and a possible tapering 
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strategy [114]. Threes studies, nevertheless, focused on SLE in complete remission (including 
inactive SLE with negative serology) without therapy (with or without antimalarials) [106,108,115].  
In the study by Urowitz et al., prolonged remission was defined as a 5-year consecutive period of no 
disease activity (SLE disease activity index, SLEDAI = 0) and without treatment (corticosteroids, 
antimalarials, or immunosuppressants). Out of 703 patients, only 12 patients (1.7%) had prolonged 
complete remission of at least 5 years with no treatment [115]. Zen et al. defined remission as 
prolonged when lasting ≥5 consecutive years. The complete remission corresponded to the absence 
of disease activity (SLEDAI-2000 =0) in corticosteroid-free and immunosuppressant-free patients. 
During the 5-year follow-up, 16 patients (7.1%) achieved prolonged complete remission [106]. 
Medina-Quiñones studied lupus patients achieving a complete remission, without clinical or 
serologic features and no treatment with steroids and immunosuppressive drugs for at least 3 years. 
Overall 77 patients (14.5%) achieved complete remission for at least 3 years [108].  
 
In lupus nephritis, negative serology does not predict a successful withdrawal of therapy. LoE 
3b 
Regarding lupus nephritis, only one study partially covered our research question. Moroni et al. 
reported their cumulative experience with treatment withdrawal in patients with biopsy-proven 
lupus nephritis with a follow-up of at least 5 years [116]. The authors completely stopped treatment 
in 52 of 161 (32 %) patients with class III, IV or V lupus nephritis. The decision of interrupting 
therapy was taken for those patients who had achieved a stable clinical remission and did not show 
any renal or extra-renal flare. Of 52 patients who stopped therapy, 32 (61.5 %) never developed 
new flares and continued without any therapy for the subsequent 101.8 months (range 44–180 
months) of observation after interruption of treatment. The other 20 patients (38 %) had at least one 
flare. No difference in the prevalence of hypocomplementemia and anti-dsDNA antibodies was 
observed among patients with and without flares [116]. 
The therapeutic scheme to be adopted in lupus nephritis during complete remission, when and how 
to reduce corticosteroids and immunosuppressants are unanswered questions, as well as it is not 
clear the role of serology in spacing/tapering strategy [117]. Recently a position paper has 
specifically addressed this point [118]. The experts have emphasized that the essential prerequisite 
for a safe withdraw of therapy is patient's remission. The authors have remembered that special 
attention must be given to tapering slowly, progressively and under strict medical surveillance for 
avoiding severe or irreversible renal failure after an abrupt discontinuation [118].  
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Available data demonstrated that baseline BAFF serum levels do not predict response to 
Belimumab in SLE patients. Other baseline biomarkers, such as high dose of glucocorticoids,  
low complement fragment C3 or C4, positivity to anti-dsDNA, might be useful in predicting 
response to Belimumab. LoE 1b 
Wallance et al. reported the results of the phase II randomized clinical trial on the use of 
Belimumab in addition to standard of care (SOC) in 449 active SLE patients [119]. Considering the 
serologically active subgroup (ANA titer >1:80 and/or anti-dsDNA >30 IU/ml), a significant greater 
proportion of patients treated with Belimumab reached the SLE Responder Index (SRI) compared 
to placebo (46% versus 29%). In the exploratory subgroup analysis, the mean percent change in 
SELENA-SLEDAI from baseline to week 52 was compared after stratification of patients according 
several biomarkers. A significant reduction in SELENA-SLEDAI was observed in patients treated 
with daily dose of prednisone ≥ 7.5 mg, in seropositive patients, in patients positive for ANA or 
anti-dsDNA or with low complement fragment components C3 or C4. Nevertheless, the reduction 
of SELENA-SLEDAI in patients with serum BAFF above the limit of detection compared with 
patients with undetectable BAFF did not reach the statistical significance [119]. Roth et al  
performed a post hoc analysis of pooled data from phase III clinical trials BLISS-52 and BLISS-76. 
In the efficacy analysis, 1108 SLE patients were stratified according to baseline BAFF serum levels 
(≥ 2 ng/ml verus < 2 ng/ml). In both subgroups (high and low basal BAFF) about half of patients 
achieved the reduction of SELENA-SLEDAI of almost 4 point and the SRI response at week 52 
[120]. Moreover, in both subgroups, the study outcomes were reached in the first 24 weeks and 
approximately maintained over time. The post-hoc analysis did not provide a direct statistical 
comparison of subgroups. However, numerically greater differences in study outcomes for 
Belimumab treated patients versus placebo were reported in the groups with high basal BAFF 
compared to the low basal BAFF group [120]. 
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7. APS Working Group 
Antiphospholipid syndrome (APS)  is an autoimmune disease clinically characterized by vascular 
thrombosis and pregnancy morbidity. Diagnosis is confirmed by the persistent presence of anti-
phospholipid antibodies (aPL) in patients’ plasma [121]. At present, three aPL assays are included 
in the classification criteria: Lupus Anticoagulant (LA), anticardiolipin (aCL) antibodies and anti-
β2glycoprotein I (anti-β2GPI) antibodies of IgG and/or IgM isotype [122]. In the last decade, a 
number of new tests, with variable sensibility and specificity, have been proposed as additional 
serological biomarkers of APS. Among them, anti-phosphatidylserine/prothrombin (anti-PS/PT) 
antibodies and epitope specific anti-beta2GPI antibodies have been suggested to display higher 
diagnostic and prognostic value for APS [123]. As a matter of fact, β2GPI and pro-thrombin have 
been addresses as the most important antigenic targets of aPL [123].   
 
7.1 Anti-β2GPI antibodies  
β2GPI is a positively charged glycoprotein composed by 5 domains. Several studies have shown 
that anti-β2GPI autoantibodies can be directed against different domains, even if domain I (D1) has 
been identified as the immune-dominant epitope in APS [124]. Moreover, this subpopulation of 
autoantibodies has been demonstrated to play a pathogenic role in APS [125-127]. On the contrary, 
antibodies targeting the fourth and fifth domain (D4/5) of the molecule have been identified in aPL 
asymptomatic carriers and in patients with infectious diseases, atopic dermatitis and babies born 
from patients with autoimmune diseases [128,129]. To assess the diagnostic and prognostic value of 
epitope specific anti-beta2GPI antibodies, a systematic review of the literature, from July 2007 to 
July 2017, including randomized clinical studies, observational studies and reviews and on APS, 
has been performed.  Of the 25 potentially relevant publications, 15 studies have been selected for 
analysis. Pulling together the results of 11 papers, for a total of 1585 patients, the overall estimated 
median prevalence of anti-D1 antibodies was 43%, ranging from 26.7% in SLE patients to 55.4% in 
primary APS [130].  
 
The addition of anti-domain I to laboratory classification criteria seems to increase the risk of 
thrombosis. LoE5 
Several different studies have shown a significant association of anti-D1 positivity to the risk of 
thrombosis, while the correlation with pregnancy morbidity was less evident [130-134]. 
Interestingly, anti-D1 positivity has been associated to triple aPL positivity, LA positivity and the 
presence of an additional autoimmune disease and higher anti-D1 titers have been observed in triple 
24 
 
aPL positive APS patients and in patients with a history of thrombosis [130-134]. By contrast, only 
3 studies reported the prevalence and clinical significance of anti-D4/5 autoantibodies. All these 
papers show that anti-D4/5 are more prevalent in asymptomatic aPL positive subjects 
[128,129,135].  
 
There is no evidence that anti-domain I  can substitute anti-beta2GPI I. LoE5   
Even if anti-D1 positivity has been clearly associated with the risk of thrombosis, a relevant 
prognostic value of this subgroup of autoantibodies for pregnancy complications is still to be 
confirmed [130-134]. In several different studies, anti-
a higher prognostic value than anti-D1 for thrombotic events [131,136,137]. Moreover, Andreoli et 
al. have reported that a small but relevant proportion of APS patients can display anti-
positivity even if they do not react with domain 1 [129]. At present, anti-domain I can be considered 
an additional, rather than an alternative, prognostic marker of APS.   
 
7.2 Anti-PS/PT antibodies 
Among new serological biomarkers of APS, antibodies specific to phospholipid-binding plasma 
proteins, phospholipid–protein complexes, and anionic phospholipids other than cardiolipin 
(including phosphatidylserine, phosphatidylinositol and phosphatidic acid). Antibodies against 
human prothrombin (aPT) and the complex of prothrombin bound phosphatidylserine (aPS/PT) 
have been strongly associated to the APS, even if their clinical relevance and diagnostic utility 
remain to be fully elucidated [138]. Although, it seems that aPT and aPS/PT belong to different 
autoantibodies families, they can both be present in the same patient [138-143].  
 
The presence of anti-PS/PT seems to increase the risk of clinical manifestations of APS. LoE5 
Current evidence suggest that aPS/PT measurement could help in the evaluation possible adverse 
pregnancy outcomes and thrombosis in patients suspected of suffering from APS and the 
assessment of thrombotic risk in patients with previous thrombosis and/or Systemic Lupus 
Erythematosus (SLE) [138,139]. A systematic review of Sciascia S, et al. reported an increased risk 
of thrombosis associated to aPT and aPS/PT (OR 2.3 [95%CI 1.72–3.5]) [139]. Moreover, aPS/PT 
seemed to be a stronger risk factor for thrombosis, both arterial and/or venous than aPT (OR 5.11 
[95%CI 4.2–6.3] and OR 1.82 [95%CI 1.44–2.75], respectively). However, these promising 
associations are based on the results of 10 studies, almost all but one, retrospective reports [138]. 
Recently, the accuracy of IgG aPS/PT for APS diagnosis in heterogeneous population has been 
confirmed in a large multicenter study, reporting a higher prevalence of aPS/PT IgG in APS patients 
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than in those without (47% versus 12%), with an OR of 6.4. In this study, sensitivity, specificity, 
LR + and LR- for APS diagnosis were 47%, 88%, 3.9 and 0.6, respectively [140]. Moreover, Hoxha 
et al. showed a positive association between IgM aPS/PT titres and both vascular thrombosis and 
pregnancy morbidity. Additionally, IgG aPS/PT was significantly associated with venous 
thrombosis [142].  
 
The presence of anti-PS/PT seems to identify very few patients with the so called seronegative 
APS. LoE5 
The concept of the so called seronegative APS (SNAPS) was introduced in 2003 to identify patients 
with highly suggestive manifestations of APS, but persistently negative for the classification 
laboratory criteria [144]. In the past 5 years, research has been focused on the identification of 
“new” aPL, not included in the serological criteria, in seronegative APS patients (3,20,22). Few 
studies have reported a relevant prevalence of anti-PS/PT antibodies in SNAPS patients. Amengual 
et al found an IgG aPS/PT antibody positivity in 6% of 17 patients with clinical manifestations of 
APS but negative for the classification laboratory criteria [141]. More recently, Shi et al, showed 
that 51% of patients with SNAPS had IgG and/or IgM anti-PS/PT antibodies and that the 
prevalence of anti-PS/PT was significantly higher in SNAPS patients compared to SLE patients 
[145].  
Taking together these findings, anti-D1 and anti-PS/PT antibodies can currently be addressed as 
potential additional serological biomarkers of APS, that can help for a better stratification of 
thrombotic and obstetric risk in APS, in combination with the classification APS laboratory 
markers. More prospective clinical studies are needed in order to define the specific role of aPS/PT 
as a potential biomarker of APS diagnosis. 
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8. pSS Working Group 
 
pSS is an autoimmune disease characterized by an inflammatory infiltrate affecting the exocrine 
glands, mainly the salivary and lacrimal glands, which may lead to a decrease in the glandular 
function. [146]. The main symptoms include dryness of the mouth and eyes. Some extra-glandular 
features may be observed, such as vasculitis, interstitial lung disease, interstitial nephritis or severe 
cryoglobulinaemic vasculitis and central nervous system involvement [147]. Furthermore, a 
significant percentage of pSS patients may develop B cell lymphoma [148]. Given the clinical 
heterogeneity and outcome of these patients, due to the different involvement observed in target 
organs, an early identification of the patient’s subsets, particularly for the subgroup of patients 
prone to lymphoma development remains a major challenge [149]. So far, there is a strong need for 
new predictive clinical or biologic biomarkers, which could, at baseline, identify those patients with 
a poor outcome, and drive the best optimal therapeutic intervention, tailored to the clinical 
phenotype of the patients. Possible predictive biomarkers of unfavourable outcomes in pSS include 
serum CXCL13 and BAFF levels, and the presence of germinal centre (GC)-like structures in minor 
salivary gland (MSG) tissue. CXCL13 is a chemokine involved in the formation and maintenance 
of GC-like structures in autoimmune diseases [150]. Data suggest it may function as a biomarker of 
GC formation following vaccination for example [151]. BAFF is essential for B cell survival and 
GC maintenance [152,153]. Different studies reported higher levels of serum CXCL13 and BAFF 
in pSS patients who developed lymphoma [154,155]. GC-like structures in MSG biopsies are 
associated with more severe disease and with the presence of autoantibodies and their presence and 
function in MSG may be associated with the lymphoma risk [156]. At present there is a general 
consensus in available literature that in pSS patients low C4, cryoglobulins, purpura, vasculitis and 
parotid swelling are strongly associated with lymphoma development  [148]. 
  
The predictive value of CXCL13 in pSS, for both poor prognosis and therapeutic response, 
remains to be clarified. LoE 2b 
CXCL13 is overexpressed in different chronic inflammatory diseases and is part of lymphoid tissue 
neogenesis, notably in the segregation of T and B cells into the T-cell zone and B-cell follicles 
[150]. In pSS salivary glands CXCL13 may directly control the formation and maintenance of 
functional ELSs and may promote, in a subset of patients the progressive development to 
lymphoma. CXCL13 levels significantly correlate with ESSDAI and, CXCL13 serum levels are 
significantly higher in pSS patients with an active disease (ESSDAI ≥ 5) [150,154]. In a Japanese 
cohort of 88 pSS patients CXCL13 serum levels correlate with lymphadenopathy, glandular, 
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pulmonary and biologic domains. Furthermore, the Authors found a correlation between CXCL13 
serum levels and hypergammaglobulinemia, underlying the possible correlation between the 
biomolecular status of salivary gland pathology and lymphomagenesis [158]. Furthermore, 
increased CXCL13 serum levels have been shown in pSS patients with the highest levels observed 
in patients with lymphoma [154]. Interestingly, the baseline CXCL13 levels of those patients who 
developed lymphoma during follow-up, were higher than the levels observed in patients who did 
not develop lymphoma  [154]. These data should be confirmed in larger studies. In a small open 
label study of abatacept in pSS, reduction on CXCL13 levels correlated with reduction in ESSDAI 
scores [159], but this requires confirmation in larger, randomised controlled trials. 
 
The predictive value of baseline BAFF levels for lymphoma development and therapeutic 
response to RTX should be further assessed. LoE 2b. 
BAFF levels are critical for peripheral B cell survival and differentiation, GC-like structure 
formation, plasma cell survival and IgG and IgE class switching. Due to these activities, BAFF may 
play a crucial role in pSS pathogenesis and in GC formation [160]. In fact, different studies show a 
correlation between BAFF serum levels and ESSDAI scores, especially for lymphadenopathy, 
glandular and pulmonary domains [155,158]. Furthermore, BAFF serum levels are higher in pSS 
patients with lymphoma and, in this setting, increased BAFF levels at diagnosis, are significantly 
associated with lymphoma development, as confirmed by multivariate analysis [154]. Increased 
BAFF serum levels also seem to be predictive of rituximab (RTX) treatment failure, suggesting a 
possible predictive role of BAFF serum levels in identifying a subset of patients suitable to be 
treated with this B-cell depleting agent [161]. On the contrary, data from a small open label study 
suggest that serum BAFF levels are not predictive for clinical to belimumab [162]. Although these 
results look very promising for personalised medicine, they have to be confirmed in larger cohorts 
before being helpful in daily clinical setting.  
 
The clinical utility of the presence of GC-like structures, in MSGs, to predict lymphoma 
development should be further assessed with standardization of technique and multicentre 
studies given the relatively low incidence of lymphoma. LoE 3b 
It has been shown that approximately 25% of pSS patients display GC-like structures in their 
salivary glands, and these patients have more severe disease in terms of higher salivary gland focus 
score, higher prevalence of rheumatoid factor, anti-SSA, and anti-SSB antibodies [163]. 
Approximately 5% of patients with pSS will develop non-Hodgkin B-cell lymphomas of mucosal-
associated lymphoid tissue, commonly in the parotid glands. Different reports describe the 
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association between GC-like structures and lymphoma development, highlighting that the detection 
of GC-like structures, by H&E staining, may be a highly predictive and an easy-to-obtain marker 
for lymphoma development [156]. Two different retrospective small cohort studies showed that the 
development of lymphoma in pSS patients was associated with the presence of GC-like structures in 
MSG biopsies at the time of diagnosis [163,164]. Another observational retrospective study did not 
find a strong association with lymphoma development but confirmed that GC-like structures in 
MSGs were associated with the presence of systemic manifestations [165]. The absence of GC-like 
structures in MSGs has been associated with a high negative predictive value for lymphoma [163]. 
However not all studies have confirmed an association of GC-like structures and lymphoma 
development [166,167] and the majority of studies investigating  this relationship have issues of 
study design, being generally retrospective studies, with small populations of patients, and using 
different methods of case identification. 
The identification of the GC-like structures should ideally be confirmed by IHC in order to identify 
the degree of organisation. In fact, some IHC studies, have failed to confirm the presence of GC-
like structures observed by H&E [156]. Further work to standardise of markers to be used is 
required however due to the potential importance of this topic [168], a strong scientific agreement 
should be reached regarding the appropriate procedures to draw a definitive conclusion. 
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9. Discussion  
This work derived from a systematic review of available literature and International Experts’ 
Consensus may provide a comprehensive highlight of the role of biomarkers in management of 
patients affected by autoimmune rheumatic diseases treated by conventional and/or biological 
therapies. The main objective of this work would be to counsel physicians on the suitable way to 
address the possible role of mechanistic, clinical and therapeutic markers in this context. Our paper 
synthesises key points and new information, largely from recent or ongoing medical research 
derived from technical review, that may have implications for management of these patients [169].  
The continued identification of new biomarkers specific to autoimmune rheumatic disease is crucial 
for translation into personalised medicine, in terms of patient management. In fact, the personalised 
medicine is an emerging practice of medicine that uses the patients’ phenotype to guide decisions 
made in regard to the diagnosis, prevention and treatment of diseases [170]. Biomarkers profiling 
may be useful for tailoring the right therapeutic strategy for the right patient at the right time, and/or 
to onset of a specific complications [171,172].  
Despite providing a comprehensive synthesis of the current available literature, this review is 
impaired from major limitations and, therefore, all the results should be cautiously interpreted. The 
main limitation is related to the poor methodological quality of a vast percentage of the included 
studies, mainly observational studies providing less reliable findings when compared with possible 
randomised controlled trials primarily and specifically designed. On these bases, it could be 
difficult to perform comparisons between extracted data and future specific designed studies are 
needed to entirely clarify these features. On the other side, it must be pointed out that autoimmune 
diseases are rare diseases and organising specific designed studies to investigate the role of 
biomarkers may be a challenge. In addition, our consensus statements do not provide specific 
algorithms or guidelines for practice because these depend on different variables, such as cost, 
expertise and practice circumstances. 
In conclusion, the results derived from our systematic review and International Experts’ Consensus 
confirmed that the better understanding and targeting of existing therapies is still an important field 
of research. Biomarkers and personalised medicine would represent the key points in the future 
management of patients affected by autoimmune rheumatic diseases.  
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Table 1.  
Statements LoE 
  
RA Working Group  
  
In a population-based setting, higher level of anti-cyclic citrullinated peptide (anti-
CCP), defined as ≥3-fold the ULN, might be more clinically useful for RA diagnosis.  
2b 
RF positivity together with very high levels of aCCP might be useful to discriminate 
RA patients from other rheumatic diseases.   
3 
High levels of anti-CCP and/or RF seem to correlate with higher disease activity and 
worse radiographic progression over time. High titre aCCP and RF are correlated 
with better response to rituximab, while only very high aCCP titers seem to be 
associated with better response to abatacept. 
2b 
Anti-CarP antibodies may serve as predictors of more severe radiographic 
progression in RA and potentially associated with more severe disease course 
2b 
In RA, the possible role of MBDA in predicting disease course and response to 
treatments is still controversial. 
5 
  
SpA Working Group  
  
Although enthesitis may be considered a clinical markers of PsA, there is no 
evidence showing that its presence at baseline predicts the response to different 
bDMARDs (TNFis, IL17is, IL12/IL23is). 
5 
Although data available on biomarkers for predicting therapeutic response in SpA 
are scarce, CRP in clinical practice may be useful in predicting TNFis response. 
2b 
  
SSc working group  
  
Anti-topoisomerase 1 antibody is a biomarker for faster progression of SSc-ILD 2b 
KL-6, SP-D, CCL18 may be considered as biomarkers for short-term progression of 
SSc-ILD. 
3b 
The DETECT algorithm is useful to identify SSc patients at higher risk for PAH who 
should undergo RHC. 
2a 
High levels of plasma CXCL4 may predict development of PAH in SSc patients. 2b 
High levels of serum Anti-AT1R and Anti-ETAR antibodies may predict 
development of PAH in SSc. 
2b 
  
SLE  working group  
  
There is no evidence that a negative serology predicts a successful withdrawal of 
therapy in SLE patients (with or without nephritis) in clinical remission. 
5 
In lupus nephritis, negative serology does not predict a successful withdrawal of 
therapy. 
3b 
  
APS working group  
  
The addition of anti-domain I to laboratory classification criteria seems to increase 
the risk of thrombosis. 
5 
There is no evidence that anti-domain I  can substitute anti-beta2GPI I. 5 
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The presence of anti-PS/PT seems to increase the risk of clinical manifestations of 
APS. 
5 
The presence of anti-PS/PT seems to identify very few patients with the so called 
seronegative APS. 
5 
  
pSS working group  
  
The predictive value of CXCL13 in pSS, for both poor prognosis and therapeutic 
response, remains to be clarified. 
2b 
The predictive value of baseline BAFF levels for lymphoma development and 
therapeutic response to RTX should be further assessed. 
2b 
The clinical utility of the presence of GC-like structures, in MSGs, to predict 
lymphoma development should be further assessed with standardization of technique 
and multicentre studies given the relatively low incidence of lymphoma. 
3b 
  
 
 
 
 
 
 
